Scribe Inks CRISPR Gene-Editing Deal with Prevail

The video discusses the CRISPR by design approach, pioneered by Jennifer Doudna and Scribe, focusing on molecular engineering for safer therapeutics. It highlights a partnership with Eli Lilly to apply this technology in neurological diseases. The rapid advancements in CRISPR technology and its potential to revolutionize medicine are explored, along with the challenges and timelines for its application. The video also touches on global collaboration and regulatory aspects, emphasizing the role of powerful universities like UC Berkeley in advancing this field.

What is the main focus of the CRISPR by design approach?

• To develop new types of CRISPR machines

• To create more active and specific therapeutics

• To focus solely on cancer treatment

• To collaborate with pharmaceutical companies

Why did the speaker choose to collaborate with Eli Lilly?

• To expand into agricultural biotechnology

• To apply CRISPR technology in neurological and neuromuscular diseases

• To develop new CRISPR tools

• To focus on cancer research

How has CRISPR technology progressed over the past decade?

• It has remained largely theoretical

• It has made significant differences in patient treatment

• It has been limited to laboratory research

• It has been used only in agricultural settings

What is the expected timeline for CRISPR's impact on medicine?

• It is already fully implemented

• Somewhere between the next year and 10 years

• Within the next year

• In the next 50 years

Which institution is mentioned as a key collaborator in CRISPR technology development?

• Stanford University

• MIT

• Harvard University

• UC Berkeley